Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 7 for:    IMO-2125 OR tilsotolimod | Cancer

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03865082
Recruitment Status : Recruiting
First Posted : March 6, 2019
Last Update Posted : November 2, 2020
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Idera Pharmaceuticals, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : April 2022